{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:59:35Z","timestamp":1791914375436,"version":"4.3.4"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Breast cancer (BC), as the most common malignant tumor among women globally, faces numerous challenges in treatment. Currently, although the combination of surgical resection with various treatment modalities such as chemotherapy, radiotherapy, and immunotherapy can improve patient survival rates, most BC patients are diagnosed at an advanced stage. Additionally, traditional small-molecule targeted anticancer drugs used during chemotherapy suffer from issues such as low target selectivity and frequent occurrence of acquired resistance, leading to suboptimal therapeutic outcomes. In recent years, tumor immunotherapy has achieved significant progress. Notably, cancer vaccines, as a strategy within tumor immunotherapy, represent a promising therapeutic approach by inducing tumor-specific immune responses. However, cancer vaccines also face several limitations, such as the strong systemic toxicity of immune adjuvants and the low immunogenicity of tumor antigens. An ideal cancer vaccine should sufficiently stimulate the body to generate a potent tumor-specific immune response while exhibiting low side effects. With innovations in nanotechnology within the medical field, nanotechnology can help overcome the limitations of traditional vaccines in the realm of vaccination. This review summarizes various nanomaterial carriers applied in the manufacturing of nanovaccines. These nanomaterials exhibit excellent biocompatibility, adjuvant activity, and immunogenicity. Furthermore, we discuss and summarize preparation strategies to enhance antitumor immune efficacy, including the use of tumor neoantigens to improve antigen presentation, the application of tumor cell membrane-based biomimetic nanotechnology to promote targeted delivery of nanovaccines, nanovaccine delivery platforms targeting the tumor microenvironment (TME), and novel strategies for combined application with nanovaccines. As an emerging strategy for BC immunotherapy, nanovaccines offer a novel approach to address the challenges of BC treatment and post-surgical recurrence by enabling precise delivery of tumor antigens, efficient activation of immune responses, and remodeling of the tumor microenvironment.<\/jats:p>","DOI":"10.3389\/fphar.2025.1691991","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T05:31:33Z","timestamp":1760592693000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Novel strategies for nanovaccine application in breast cancer treatment"],"prefix":"10.3389","volume":"16","author":[{"given":"Huan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.3390\/vaccines10111946","article-title":"Nanoparticle-based delivery systems for vaccines","volume":"10","author":"Bezbaruah","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/b978-0-12-391858-1.00008-3","article-title":"Targeting nanoparticles to dendritic cells for immunotherapy","volume":"509","author":"Cruz","year":"2012","journal-title":"Methods Enzymol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1080\/14760584.2021.1984890","article-title":"Nanovaccine: an emerging strategy","volume":"20","author":"Das","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"B4","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jconrel.2022.07.036","article-title":"Breast cancer vaccines: new insights into immunomodulatory and nano-therapeutic approaches","volume":"349","author":"Davodabadi","year":"2022","journal-title":"J. Control Release"},{"key":"B5","doi-asserted-by":"publisher","first-page":"111543","DOI":"10.1016\/j.intimp.2024.111543","article-title":"Peptide nanovaccine in melanoma immunotherapy","volume":"129","author":"Dehghankhold","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","article-title":"Pathogenesis of triple-negative breast cancer","volume":"17","author":"Derakhshan","year":"2022","journal-title":"Annu. Rev. Pathol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e2401631","DOI":"10.1002\/smll.202401631","article-title":"Cancer nanovaccines: nanomaterials and clinical perspectives","volume":"20","author":"Desai","year":"2024","journal-title":"Small"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e2301420","DOI":"10.1002\/smll.202301420","article-title":"Construction of pH-Sensitive nanovaccines encapsulating tumor cell lysates and immune adjuvants for breast cancer therapy","volume":"19","author":"Ding","year":"2023","journal-title":"Small"},{"key":"B9","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1038\/s41467-025-60448-3","article-title":"Neoantigens combined with in situ cancer vaccination induce personalized immunity and reshape the tumor microenvironment","volume":"16","author":"Feng","year":"2025","journal-title":"Nat. Commun."},{"key":"B10","doi-asserted-by":"publisher","first-page":"12166","DOI":"10.18632\/oncotarget.2570","article-title":"Molecular profiling and computational network analysis of TAZ-Mediated mammary tumorigenesis identifies actionable therapeutic targets","volume":"5","author":"Frangou","year":"2014","journal-title":"Oncotarget"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.apsb.2024.12.017","article-title":"NIR-II-activated whole-cell vaccine with ultra-efficient semiconducting diradical oligomers for breast carcinoma growth and metastasis inhibition","volume":"15","author":"Gao","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"B12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3233\/bd-210050","article-title":"Breast cancer stem cell population in different molecular subtypes of breast cancer","volume":"41","author":"Gupta","year":"2022","journal-title":"Breast Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/s41568-024-00714-6","article-title":"Towards targeting the breast cancer immune microenvironment","volume":"24","author":"Harris","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"7783","DOI":"10.1021\/acs.nanolett.0c03414","article-title":"Cancer immunotherapy via targeting cancer stem cells using vaccine nanodiscs","volume":"20","author":"Hassani Najafabadi","year":"2020","journal-title":"Nano Lett."},{"key":"B15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/intimm\/dxw027","article-title":"The present status and future prospects of peptide-based cancer vaccines","volume":"28","author":"Hirayama","year":"2016","journal-title":"Int. Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.3390\/cancers13122909","article-title":"Development of a virus-like particle-based Anti-HER2 breast cancer vaccine","volume":"13","author":"Hu","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"123380","DOI":"10.1016\/j.biomaterials.2025.123380","article-title":"An artificial-enzyme-equipped immunoregulator blocks platelet-mediated breast cancer hematogenous metastasis","volume":"322","author":"Hu","year":"","journal-title":"Biomaterials"},{"key":"B18","doi-asserted-by":"publisher","first-page":"102798","DOI":"10.1016\/j.nantod.2025.102798","article-title":"Perivascular delivery of photothermal-immunotherapy nanovaccine bypasses blood circulation to enhance the antitumor immune response of breast cancer","volume":"64","author":"Hu","year":"","journal-title":"Nano Today"},{"key":"B19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.semcancer.2021.06.015","article-title":"Cancer stem cells in TNBC","volume":"82","author":"Hua","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"121808","DOI":"10.1016\/j.biomaterials.2022.121808","article-title":"In situ photothermal nano-vaccine based on tumor cell membrane-coated Black phosphorus-Au for photo-immunotherapy of metastatic breast tumors","volume":"289","author":"Huang","year":"2022","journal-title":"Biomaterials"},{"key":"B21","doi-asserted-by":"publisher","first-page":"101136","DOI":"10.1016\/j.mtbio.2024.101136","article-title":"Robust anti-tumor immunity through the integration of targeted lipid nanoparticle-based mRNA nanovaccines with PD-1\/PD-L1 blockade","volume":"27","author":"Jin","year":"2024","journal-title":"Mater Today Bio"},{"key":"B22","doi-asserted-by":"publisher","first-page":"120499","DOI":"10.1016\/j.lfs.2022.120499","article-title":"Photothermal therapy-mediated autophagy in breast cancer treatment: progress and trends","volume":"298","author":"Kadkhoda","year":"2022","journal-title":"Life Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2021.0459","article-title":"Breast cancer: presentation, investigation and management","volume":"83","author":"Katsura","year":"2022","journal-title":"Br. J. Hosp. Med. (Lond)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"6427","DOI":"10.2147\/ijn.S388996","article-title":"Combined photodynamic and photothermal therapy and immunotherapy for cancer treatment: a review","volume":"17","author":"Kong","year":"2022","journal-title":"Int. J. Nanomedicine"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e2101239","DOI":"10.1002\/adhm.202101239","article-title":"Conjugation-free multilamellar protein-lipid hybrid vesicles for multifaceted immune responses","volume":"10","author":"Koo","year":"2021","journal-title":"Adv. Healthc. Mater"},{"key":"B26","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jare.2023.02.005","article-title":"A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer","volume":"54","author":"Kumar","year":"2023","journal-title":"J. Adv. Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12943-024-01990-4","article-title":"Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer","volume":"23","author":"Kundu","year":"2024","journal-title":"Mol. Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ajps.2020.06.006","article-title":"A biomimetic antitumor nanovaccine based on biocompatible calcium pyrophosphate and tumor cell membrane antigens","volume":"16","author":"Li","year":"2021","journal-title":"Asian J. Pharm. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent advances in therapeutic strategies for triple-negative breast cancer","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.bioactmat.2022.08.028","article-title":"A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-PD-L1 antibody","volume":"21","author":"Li","year":"2023","journal-title":"Bioact. Mater"},{"key":"B31","doi-asserted-by":"publisher","first-page":"217111","DOI":"10.1016\/j.canlet.2024.217111","article-title":"Intratumoral injection of mRNA encoding survivin in combination with STAT3 inhibitor stattic enhances antitumor effects","volume":"598","author":"Li","year":"","journal-title":"Cancer Lett."},{"key":"B32","doi-asserted-by":"publisher","first-page":"122626","DOI":"10.1016\/j.biomaterials.2024.122626","article-title":"Manganese oxide-constructed multifunctional biomimetic nanovaccine for robust tumor-specific T cell priming and chemodynamic therapy","volume":"309","author":"Li","year":"","journal-title":"Biomaterials"},{"key":"B33","doi-asserted-by":"publisher","first-page":"4783","DOI":"10.1038\/s41467-025-59977-8","article-title":"Neoantigen enriched biomimetic nanovaccine for personalized cancer immunotherapy","volume":"16","author":"Li","year":"2025","journal-title":"Nat. Commun."},{"key":"B34","doi-asserted-by":"publisher","first-page":"101298","DOI":"10.1016\/j.tranon.2021.101298","article-title":"Combination of CTLA-4 blockade with MUC1 mRNA nanovaccine induces enhanced anti-tumor CTL activity by modulating tumor microenvironment of triple negative breast cancer","volume":"15","author":"Lin","year":"2022","journal-title":"Transl. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ymthe.2017.10.020","article-title":"Combination immunotherapy of MUC1 mRNA nano-Vaccine and CTLA-4 blockade effectively inhibits growth of triple negative breast cancer","volume":"26","author":"Liu","year":"2018","journal-title":"Mol. Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"9410","DOI":"10.1021\/acs.nanolett.1c02582","article-title":"Equipping cancer cell membrane vesicles with functional DNA as a targeted vaccine for cancer immunotherapy","volume":"21","author":"Liu","year":"2021","journal-title":"Nano Lett."},{"key":"B37","doi-asserted-by":"publisher","first-page":"9826","DOI":"10.1021\/acsnano.3c02273","article-title":"Stimuli-responsive polymeric nanovaccines toward next-generation immunotherapy","volume":"17","author":"Mao","year":"2023","journal-title":"ACS Nano"},{"key":"B38","doi-asserted-by":"publisher","first-page":"eaaw6071","DOI":"10.1126\/sciadv.aaw6071","article-title":"A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer","volume":"6","author":"Ni","year":"2020","journal-title":"Sci. Adv."},{"key":"B39","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","article-title":"Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers","volume":"19","author":"Nooraei","year":"2021","journal-title":"J. Nanobiotechnology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/vaccines13020144","article-title":"Manufacturing and financial evaluation of peptide-based neoantigen cancer vaccines for triple-negative breast cancer in the United Kingdom: opportunities and challenges","volume":"13","author":"Novakova","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s13770-022-00430-y","article-title":"Nanozyme-Based enhanced cancer immunotherapy","volume":"19","author":"Phan","year":"2022","journal-title":"Tissue Eng. Regen. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e2006000","DOI":"10.1002\/smll.202006000","article-title":"Nanovaccine-Based strategies to overcome challenges in the whole vaccination Cascade for tumor immunotherapy","volume":"17","author":"Qin","year":"2021","journal-title":"Small"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e2409590","DOI":"10.1002\/adma.202409590","article-title":"A biomimetic autophagosomes-based nanovaccine boosts anticancer immunity","volume":"36","author":"Qu","year":"2024","journal-title":"Adv. Mater"},{"key":"B44","doi-asserted-by":"publisher","first-page":"125336","DOI":"10.1016\/j.ijpharm.2025.125336","article-title":"Cell membrane-camouflaged nanocarriers: a cutting-edge biomimetic technology to develop cancer immunotherapy","volume":"672","author":"Samanta","year":"2025","journal-title":"Int. J. Pharm."},{"key":"B45","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1039\/c9cs00648f","article-title":"Multifunctional sonosensitizers in sonodynamic cancer therapy","volume":"49","author":"Son","year":"2020","journal-title":"Chem. Soc. Rev."},{"key":"B46","doi-asserted-by":"publisher","first-page":"4998","DOI":"10.1021\/acsabm.3c00843","article-title":"Lipid- and polymer-based nanocarrier platforms for cancer vaccine delivery","volume":"7","author":"Sunoqrot","year":"2024","journal-title":"ACS Appl. Bio Mater"},{"key":"B47","doi-asserted-by":"publisher","first-page":"12455","DOI":"10.1039\/d3nr01976d","article-title":"Nanozyme: a rising star for cancer therapy","volume":"15","author":"Wang","year":"2023","journal-title":"Nanoscale"},{"key":"B48","doi-asserted-by":"publisher","first-page":"34063","DOI":"10.1021\/acsnano.4c09653","article-title":"Biomimetic dendritic cell-based nanovaccines for reprogramming the immune microenvironment to boost tumor immunotherapy","volume":"18","author":"Wang","year":"","journal-title":"ACS Nano"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e2307920","DOI":"10.1002\/advs.202307920","article-title":"Spatiotemporal controllable sono-nanovaccines driven by free-field based whole-body ultrasound for personalized cancer therapy","volume":"11","author":"Wang","year":"","journal-title":"Adv. Sci. (Weinh)"},{"key":"B50","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s40820-024-01533-y","article-title":"Engineered cancer nanovaccines: a new frontier in cancer therapy","volume":"17","author":"Wang","year":"","journal-title":"Nanomicro Lett."},{"key":"B51","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.bioactmat.2024.04.023","article-title":"Turning foes to friends: advanced \u201cin situ nanovaccine\u201d with dual immunoregulation for enhanced immunotherapy of metastatic triple-negative breast cancer","volume":"39","author":"Wang","year":"","journal-title":"Bioact. Mater"},{"key":"B52","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.actbio.2025.04.039","article-title":"A dissolvable microneedle platform for the delivery of tumor-derived total RNA nanovaccines for enhanced tumor immunotherapy","volume":"199","author":"Wang","year":"","journal-title":"Acta Biomater."},{"key":"B53","doi-asserted-by":"publisher","first-page":"6022","DOI":"10.7150\/thno.107200","article-title":"pH-responsive nano-vaccine combined with anti-PD-1 antibodies for enhanced immunotherapy of breast cancer","volume":"15","author":"Wang","year":"","journal-title":"Theranostics"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1042\/bsr20193220","article-title":"Engineering anti-cancer nanovaccine based on antigen cross-presentation","volume":"39","author":"Warrier","year":"2019","journal-title":"Biosci. Rep."},{"key":"B55","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1039\/d0nr08978h","article-title":"Biomimetic cytomembrane nanovaccines prevent breast cancer development in the long term","volume":"13","author":"Xiao","year":"2021","journal-title":"Nanoscale"},{"key":"B56","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct. Target Ther."},{"key":"B57","doi-asserted-by":"publisher","first-page":"101098","DOI":"10.1016\/j.drup.2024.101098","article-title":"Application of biomimetic nanovaccines in cancer immunotherapy: a useful strategy to help combat immunotherapy resistance","volume":"75","author":"Xu","year":"2024","journal-title":"Drug Resist Updat"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e2418894","DOI":"10.1002\/adma.202418894","article-title":"Mitochondrion-Targeted type I photodynamic therapy for agonist independent cGAS-STING activation","volume":"37","author":"Xu","year":"2025","journal-title":"Adv. Mater"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e2411361","DOI":"10.1002\/adma.202411361","article-title":"Personalized multi-epitope nanovaccine unlocks B cell-mediated multiple pathways of Antitumor immunity","volume":"37","author":"Yan","year":"2025","journal-title":"Adv. Mater"},{"key":"B60","doi-asserted-by":"publisher","first-page":"eabd1631","DOI":"10.1126\/sciadv.abd1631","article-title":"Size-transformable antigen-presenting cell-mimicking nanovesicles potentiate effective cancer immunotherapy","volume":"6","author":"Yang","year":"2020","journal-title":"Sci. Adv."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e2204365","DOI":"10.1002\/advs.202204365","article-title":"Emerging sonodynamic therapy-based nanomedicines for cancer immunotherapy","volume":"10","author":"Yang","year":"2023","journal-title":"Adv. Sci. (Weinh)"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e2400630","DOI":"10.1002\/advs.202400630","article-title":"Leveraging senescent cancer cell membrane to potentiate cancer immunotherapy through biomimetic nanovaccine","volume":"11","author":"Yang","year":"2024","journal-title":"Adv. Sci. (Weinh)"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1211262","DOI":"10.3389\/fonc.2023.1211262","article-title":"Research progress of nanovaccine in anti-tumor immunotherapy","volume":"13","author":"Yao","year":"2023","journal-title":"Front. Oncol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"11752","DOI":"10.1021\/acsami.4c20487","article-title":"Cold exposure therapy enhances single-atom nanozyme-mediated cancer vaccine therapy","volume":"17","author":"Ye","year":"2025","journal-title":"ACS Appl. Mater Interfaces"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/s41565-025-01952-x","article-title":"A nanovaccine targeting cancer stem cells and bulk cancer cells for postoperative cancer immunotherapy","volume":"20","author":"You","year":"2025","journal-title":"Nat. Nanotechnol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"101498","DOI":"10.1016\/j.nantod.2022.101498","article-title":"Self-assembled nanospheres mediate phototherapy and deliver CpG oligodeoxynucleotides to enhance cancer immunotherapy of breast cancer and melanoma","volume":"44","author":"Yu","year":"2022","journal-title":"Nano Today"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e1559","DOI":"10.1002\/wnan.1559","article-title":"Nanovaccines for cancer immunotherapy","volume":"11","author":"Zhang","year":"2019","journal-title":"Wiley Interdiscip. Rev. Nanomed Nanobiotechnol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"19509","DOI":"10.1021\/acsnano.2c09708","article-title":"Sulfonium-Driven neoantigen-released DNA nanodevice as a precise vaccine for tumor immunotherapy and prevention","volume":"16","author":"Zhang","year":"2022","journal-title":"ACS Nano"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1038\/s41596-022-00713-7","article-title":"Nanocarriers based on bacterial membrane materials for cancer vaccine delivery","volume":"17","author":"Zhao","year":"2022","journal-title":"Nat. Protoc."},{"key":"B70","doi-asserted-by":"publisher","first-page":"e2302922","DOI":"10.1002\/smll.202302922","article-title":"Neoantigen-Based nanovaccine in combination with immune checkpoint inhibitors abolish postsurgical tumor recurrence and metastasis","volume":"19","author":"Zheng","year":"2023","journal-title":"Small"},{"key":"B71","doi-asserted-by":"publisher","first-page":"100955","DOI":"10.1016\/j.mtbio.2024.100955","article-title":"Human serum albumin as the carrier to fabricate STING-activating peptide nanovaccine for antitumor immunotherapy","volume":"25","author":"Zheng","year":"2024","journal-title":"Mater Today Bio"},{"key":"B72","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1021\/acs.nanolett.0c01140","article-title":"Engineering polymeric prodrug nanoplatform for vaccination immunotherapy of cancer","volume":"20","author":"Zhou","year":"2020","journal-title":"Nano Lett."},{"key":"B73","doi-asserted-by":"publisher","first-page":"e1881","DOI":"10.1002\/wnan.1881","article-title":"Emerging nanoparticle designs against bacterial infections","volume":"15","author":"Zhou","year":"2023","journal-title":"Wiley Interdiscip. Rev. Nanomed Nanobiotechnol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1016\/j.apsb.2023.03.004","article-title":"Immune cell membrane-based biomimetic nanomedicine for treating cancer metastasis","volume":"13","author":"Zhu","year":"2023","journal-title":"Acta Pharm. Sin. B"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1691991\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T05:31:34Z","timestamp":1760592694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1691991\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":74,"alternative-id":["10.3389\/fphar.2025.1691991"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1691991","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"article-number":"1691991"}}